Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Clifton Craig Mo, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Desai S, Mo C, Gaglione EM, Yuan CM, Stetler-Stevenson M, Tian X, Maric I, Wake L, Farooqui MZ, Drinkwater DC, Soto S, Valdez J, Hughes TE, Nierman P, Lotter J, Marti GE, Pleyer C, Sun C, Superata J, Nichols C, Herman SEM, Lindorfer MA, Taylor RP, Wiestner A, Ahn IE. Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. Leuk Lymphoma. 2021 Mar 02; 1-17. PMID: 33653216.
    Citations:    Fields:    
  2. Maurer K, Saucier A, Kim HT, Acharya U, Mo CC, Porter J, Albert C, Cutler C, Antin JH, Koreth J, Gooptu M, Romee R, Wu CJ, Soiffer RJ, Nikiforow S, Jacobson C, Ho VT. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871. PMID: 33560397.
    Citations: 2     Fields:    Translation:Humans
  3. Calabretta E, Moraleda JM, Iacobelli M, Jara R, Vlodavsky I, O'Gorman P, Pagliuca A, Mo C, Baron RM, Aghemo A, Soiffer R, Fareed J, Carlo-Stella C, Richardson P. COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol. 2021 04; 193(1):43-51. PMID: 33538335.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  4. Kazandjian D, Mo CC, Landgren O, Richardson PG. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020 12; 191(5):692-703. PMID: 32501533.
    Citations:    Fields:    Translation:Humans
  5. Jamison LS, Mo CC, Kwok M. Pericardial relapse of multiple myeloma. BMJ Case Rep. 2020 Apr 23; 13(4). PMID: 32332043.
    Citations:    Fields:    Translation:Humans
  6. Mo CC, Richardson PG. Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile. Br J Haematol. 2020 02; 188(4):483-485. PMID: 31566715.
    Citations: 1     Fields:    Translation:Humans
  7. Kwok M, Wu SP, Mo C, Summers T, Roschewski M. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas. Curr Treat Options Oncol. 2016 09; 17(9):47. PMID: 27461036.
    Citations: 4     Fields:    Translation:Humans
  8. Korde N, Zhang Y, Loeliger K, Poon A, Simakova O, Zingone A, Costello R, Childs R, Noel P, Silver S, Kwok M, Mo C, Young N, Landgren O, Sloand E, Maric I. Monoclonal gammopathy-associated pure red cell aplasia. Br J Haematol. 2016 06; 173(6):876-83. PMID: 26999424.
    Citations: 5     Fields:    Translation:HumansCells
  9. Ramos NR, Mo CC, Karp JE, Hourigan CS. Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Med. 2015 Apr; 4(4):665-95. PMID: 25932335.
    Citations: 35     
  10. Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B, Lee E, Marti G, Wilson WH, Taylor RP, Wiestner A. Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Haematologica. 2013 Aug; 98(8):1259-63. PMID: 23716541.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  11. Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011 Jan 13; 117(2):542-52. PMID: 20956803.
    Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
  12. Mo C, Vire B, Wiestner A. Rituximab: therapeutic benefit! Vitamin R? Semin Hematol. 2010 Apr; 47(2):105-6. PMID: 20350656.
    Citations: 2     Fields:    Translation:HumansCells
  13. Greenburg DL, Mo CC, Hemmer PA. IVIG for thymoma-associated pseudo-obstruction: report of successful treatment. Eur Neurol. 2007; 58(2):116-7. PMID: 17570918.
    Citations: 1     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mo's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (99)
Co-Authors (14)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.